Skip to main content
Delfa

← All assets

Simvastatin

6 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

6

Ongoing

0

Recruiting

0

Completed

6

Sites

48

Countries

1

Endpoints

38

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 38 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
3
Phase 3
1
Phase 4
2

Trials by status

Completed
6

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Amyloid biomarkers
11
Global cognition
10
Tau biomarkers
6
Neuroimaging
6
Function / daily living
2
Other (unclassified)
2
Fluid / digital biomarkers
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 6 of 38 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Mini-Mental State Examination (MMSE)Cognition

2

ADAS-CogCognition

2

Phosphorylated tau 181 (p-tau181)Tau

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

6 of 6

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT00053599Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study

Simvastatin

Alzheimer’s disease

Alzheimer's diseasePh 3Completed44Oct 20073
SHARPStatin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease

Simvastatin

Alzheimer’s disease

Alzheimer's diseasePh 2Completed1Sep 20132results
ESPRITEvaluating Simvastatin's Potential Role in Therapy

Simvastatin

Alzheimer’s disease

Age 35-69Ph 2Completed1Jun 20093results
NCT00303277Do HMG CoA Reductase Inhibitors Affect Abeta Levels?

pravastatin, Simvastatin

Alzheimer’s disease

Age 18-90Ph 4Completed1Apr 20053
NCT01439555Endothelial Facilitation in Alzheimer's Disease

Simvastatin, Tetrahydrobiopterin

Alzheimer’s disease

MMSE 15-26Ph 2Completed1Nov 20171results
SimBioEffects of Simvastatin on Biomarkers

Simvastatin

Alzheimer’s disease

MMSE ≥26Ph 4Completed1Oct 2015-results

Showing 1-6 of 6 trials